Press Release **For Immediate Release**

Glenmark Pharmaceuticals receives ANDA approval for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg

Mumbai, India; January 7, 2020: – Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, the generic version of Exjade®[1] Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, of Novartis Pharmaceuticals Corporation.

According to IQVIA™ sales data for the 12-month period ending November 2019, the Exjade® Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg market[2] achieved annual sales of approximately $106.4 million*.

Glenmark's current portfolio consists of 165 products authorized for distribution in the U.S. marketplace and 43 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

About Glenmark Pharmaceuticals - Glenmark Pharmaceuticals Ltd. (GPL) is a global innovative pharmaceutical company with operations in more than 50 countries primarily focused in the areas of oncology, respiratory and dermatology. Glenmark has a significant presence in generic drugs market and has improved lives of millions of patients by offering safe, affordable medications for nearly 40 years. For more information, visit www.glenmarkpharma.com

For further information, please contact:

Madhurima Gupta Jain
Glenmark, Mumbai, India
Tel: +91 22 4018 9999
Email: corpcomm@glenmarkpharma.com

[1]All brand names and trademarks are the property of their respective owners.

[2]Market includes brand and all available therapeutic equivalents

*IQVIA™ National Sales Perspectives: Retail & Non-Retail, November 2019